Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

BACKGROUND: Axitinib demonstrated greater progression-free survival vs sorafenib in a phase III study of previously treated patients with metastatic renal cell carcinoma. Here, we report patient-reported kidney-specific symptoms and health status, measured by the Functional Assessment of Cancer Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Cella, D, Escudier, B, Rini, B, Chen, C, Bhattacharyya, H, Tarazi, J, Rosbrook, B, Kim, S, Motzer, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668468/
https://www.ncbi.nlm.nih.gov/pubmed/23579211
http://dx.doi.org/10.1038/bjc.2013.145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668468/
https://www.ncbi.nlm.nih.gov/pubmed/23579211
http://dx.doi.org/10.1038/bjc.2013.145

Ejemplares similares